Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 13 2022 - 6:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2022
Commission File Number: 001-40010
Pharvaris N.V.
(Translation of registrants name into English)
J.H. Oortweg
21
2333 CH Leiden
The Netherlands
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F Form
20-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security holders
Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form
6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing
on EDGAR.
PHARVARIS N.V.
In connection with an investor event, on July 13, 2022, Pharvaris N.V. (the Company) provided a corporate update included in
a corporate presentation on its website, which, among other things, contains updated guidance with respect to the Companys Phase 2 clinical trial for the prophylactic treatment of hereditary angioedema using twice-daily dosing of the PHVS416
softgel capsules (CHAPTER-1). Based on projected enrollment rates, the Company has now refined timing of full trial enrollment and believes a more conservative estimate for reporting topline data for this
trial is the first quarter of 2023.
A copy of the corporate presentation is attached hereto as Exhibit 99.1. This Report on Form 6-K (excluding Exhibit 99.1) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number
333-263198) and Form S-8 (Registration Number 333-252897). Exhibit 99.1 to this Report on Form
6-K shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: July 13, 2022
|
|
|
PHARVARIS N.V. |
|
|
By: |
|
/s/ Berndt Modig |
Name: |
|
Berndt Modig |
Title: |
|
Chief Executive Officer |
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024